Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU and are either active, near activation or temporarily closed. The list may be sorted by Protocol Number, Lead Organization, NIH Program, Status, or Phase. Clicking to the right of each title in the header row will display an arrow, an upwards facing arrow will sort by ascending order and a downwards facing arrow will display by descending order. Each protocol number is hyperlinked and clicking on the protocol number will open a new website, the National Cancer Institute’s Clinical Trials Physicians Data Query (PDQ®). PDQ provides additional information about each clinical trial including the trial summary, eligibility criteria and a listing of sites that have the trial open. The protocol list can be exported to and Excel or CSV file or printed by selecting the icon located above the header row.

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.
#Protocol NumberLead OrganizationNIH ProgramDiseaseStatusProtocol TitlePhaseAccrual TargetAccrual Total
  • First Page
  • Previous Page
  • Page 1 of 6
  • Next Page
  • Last Page
  • Last update: 9:59:59 AM UTC
1EAY131-JECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol J; Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers, and Non-Colorectal Cancers with HER2 Amplification00
2EAY131-Z1CECOG-ACRINNCTNN/ATemporarily Closed to AccrualMATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification00
3N0577ALLIANCENCTNCNS Cancer (Primary tumor)ActiveN0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade GliomaIII361141
4RTOG-0724NRGNCTNFemale Reproductive System CancerActivePhase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical HysterectomyIII285192
5GOG-0263NRGNCTNFemale Reproductive System CancerActiveRandomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)III534297
6EAY131-S2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations00
7CALGB-30610ALLIANCENCTNLung, Mediastinal, and Pleural CancerActivePhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and EtoposideIII729694
8EAY131-EECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR00
9EAY131-GECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)00
10EAY131-Z1EECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions00
11EAY131-Z1GECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result00
12EAY131-VECOG-ACRINNCTNN/AActiveMatch Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)00
13EAY131-FECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements00
14EAY131-Z1FECOG-ACRINNCTNN/ATemporarily Closed to AccrualMATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)00
15A231701CDALLIANCENCORPBreast CancerPre-ActivationIncreasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making InterventionOther10500
16EAY131-C1ECOG-ACRINNCTNN/ATemporarily Closed to AccrualMATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification00
17EAY131-AECOG-ACRINNCTNN/AActiveEAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment00
18EAY131-MECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients with Tumors with TSC1 or TSC2 Mutations00
19EAY131-TECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations00
20EAY131-LECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors wtih mTOR Mutations00
21EAY131-K1ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol K1: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Amplifications00
22EAY131-K2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol K2: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions00
23EAY131-C2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion00
24EAY131-Z1HECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC00
25PBTC-049PBTCMISCELLANEOUSCNS Cancer (Primary tumor)ActiveA Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS TumorsI362
26PBTC-051PBTCMISCELLANEOUSCNS Cancer (Primary tumor)ActivePhase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem GliomaI459
27S1600SWOGNCORPUrothelial/ Bladder CancerPre-ActivationA Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy OutcomesIII2000
28URCC-16092URCCNCORPGastrointestinal CancerActivePhase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving ChemotherapyII860
29EAY131-Z1IECOG-ACRINNCTNN/ATemporarily Closed to AccrualMATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations00
3010106LAO-MD017ETCTNLymphomaActiveA Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory LymphomasI/II761
3110150LAO-11030ETCTNFemale Reproductive System CancerActiveA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerI/II967
3210145LAO-NCIETCTNLymphoma;Miscellaneous and Metastatic CancerActivePhase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and LymphomasI417
33EA8171ECOG-ACRINNCTNMale Reproductive System CancerActiveMultiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate CancerII8520
34A021602ALLIANCENCTNEndocrine CancerActiveRandomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)III3956
3510166LAO-MD017ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerII241
36S1703SWOGNCORPBreast CancerActiveRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast CancerOther132013
37S1712SWOGNCTNLeukemiaActiveA Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of DiseaseII842
38AGCT1532COGNCTNGerm Cell CancerActiveA Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell TumorsIII1505
39A031701ALLIANCENCTNUrothelial/ Bladder CancerActiveA Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene AlterationsII2712
40A211601ALLIANCENCORPBreast CancerActiveEvaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502III3840
41WF-97415WAKENCORPBreast CancerActiveUnderstanding and Predicting Breast Cancer Events after Treatment (UPBEAT)Other100034*
42EA5142ECOG-ACRINNCTNLung, Mediastinal, and Pleural CancerActiveAdjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersIII714640
43CITN-12CITNMISCELLANEOUSAIDS-related Malignancy and Condition;Gastrointestinal Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Lung, Mediastinal, and Pleural Cancer;Lymphoma;Miscellaneous and Metastatic Cancer;Skin CancerActivePhase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmI3934
44NRG-CC003NRGNCORPLung, Mediastinal, and Pleural CancerActiveRandomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung CancerII/III302184
459899LAO-MA036ETCTNMiscellaneous and Metastatic CancerActiveA Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid TumorsI3729
4610144LAO-NCIETCTNUrothelial/ Bladder CancerActiveA Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair DefectsII600
47NRG-GY012NRGNCTNFemale Reproductive System CancerActiveA Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial CancerII12040
48S1706SWOGNCTNBreast CancerActiveA Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast CancerII3001
49S1701SWOGNCTNLung, Mediastinal, and Pleural CancerActiveA Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaII660
5010136LAO-TX035ETCTNMiscellaneous and Metastatic CancerActiveA Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 AmplificationII321